| Bioactivity | AZD-5069 is a potent CXCR2 chemokine receptor antagonist, used for caner treatment. | ||||||||||||
| Invitro | AZD-5069 (Compound 2) acts as CXCR2 antagonist by inhibition of [125I]-IL-8 binding to human CXCR2 receptors and as inhibitor of GROα-induced Ca2+ flux in human neutrophils loaded with fluo-3 dye[1]. | ||||||||||||
| Name | AZD-5069 | ||||||||||||
| CAS | 878385-84-3 | ||||||||||||
| Formula | C18H22F2N4O5S2 | ||||||||||||
| Molar Mass | 476.52 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Norman P. Evidence on the identity of the CXCR2 antagonist AZD-5069. Expert Opin Ther Pat. 2013 Jan;23(1):113-7. |